|
FR2705686B1
(fr)
*
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
|
ATE272113T1
(de)
*
|
1994-02-16 |
2004-08-15 |
Crucell Holland Bv |
Melanoma-assoziierte antigene, epitope davon und impstoffe gegen melanoma
|
|
US6265212B1
(en)
|
1995-06-15 |
2001-07-24 |
Introgene B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
|
US6783980B2
(en)
*
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
|
DE69638058D1
(de)
*
|
1995-06-15 |
2009-11-26 |
Crucell Holland Bv |
Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
|
|
US20020068049A1
(en)
*
|
1998-09-10 |
2002-06-06 |
Henderson Daniel R. |
Tissue specific adenoviral vectors
|
|
US20040156861A1
(en)
*
|
1996-07-11 |
2004-08-12 |
Figdor Carl Gustav |
Melanoma associated peptide analogues and vaccines against melanoma
|
|
US5877011A
(en)
*
|
1996-11-20 |
1999-03-02 |
Genzyme Corporation |
Chimeric adenoviral vectors
|
|
US5849561A
(en)
*
|
1997-05-22 |
1998-12-15 |
Cornell Research Foundation, Inc. |
Method for the production of non-group C adenoviral vectors
|
|
US6696423B1
(en)
|
1997-08-29 |
2004-02-24 |
Biogen, Inc. |
Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
|
|
US20040204381A1
(en)
*
|
1997-11-12 |
2004-10-14 |
Moskal Joseph R |
Detection and treatment of glyco-enzyme-related disease
|
|
US6670188B1
(en)
|
1998-04-24 |
2003-12-30 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
|
WO1999055365A1
(en)
*
|
1998-04-30 |
1999-11-04 |
Cornell Research Foundation, Inc. |
Adenoviral vectors with tandem fiber proteins
|
|
US6413776B1
(en)
|
1998-06-12 |
2002-07-02 |
Galapagos Geonomics N.V. |
High throughput screening of gene function using adenoviral libraries for functional genomics applications
|
|
US20040043489A1
(en)
*
|
1998-07-08 |
2004-03-04 |
Menzo Havenga |
Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
|
|
US20030017138A1
(en)
*
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
|
EP1108049A2
(en)
*
|
1998-08-28 |
2001-06-20 |
Duke University |
Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences
|
|
US6929946B1
(en)
*
|
1998-11-20 |
2005-08-16 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
|
|
US6224566B1
(en)
|
1999-05-04 |
2001-05-01 |
Cardiodyne, Inc. |
Method and devices for creating a trap for confining therapeutic drugs and/or genes in the myocardium
|
|
ATE519855T1
(de)
*
|
1999-05-17 |
2011-08-15 |
Crucell Holland Bv |
Rekombinantes adenovirus des serotyps ad11
|
|
US6492169B1
(en)
*
|
1999-05-18 |
2002-12-10 |
Crucell Holland, B.V. |
Complementing cell lines
|
|
US20050232900A1
(en)
*
|
1999-05-18 |
2005-10-20 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
|
US6913922B1
(en)
*
|
1999-05-18 |
2005-07-05 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
|
EP1157999A1
(en)
*
|
2000-05-24 |
2001-11-28 |
Introgene B.V. |
Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
|
|
EP1322774A2
(en)
*
|
2000-09-20 |
2003-07-02 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for dendritic cells
|
|
DE60138403D1
(de)
*
|
2000-09-26 |
2009-05-28 |
Crucell Holland Bv |
Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
|
|
CA2439185A1
(en)
*
|
2001-02-23 |
2002-09-06 |
Novartis Ag |
Vector constructs
|
|
WO2003020893A2
(en)
*
|
2001-08-30 |
2003-03-13 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
New adenovirus type 7 vectors
|
|
US7375206B2
(en)
*
|
2002-02-22 |
2008-05-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Brother of the regulator of imprinted sites (BORIS)
|
|
NZ534866A
(en)
*
|
2002-04-25 |
2007-04-27 |
Crucell Holland B |
Means and methods for the production of adenovirus vectors
|
|
US20040106194A1
(en)
*
|
2002-08-22 |
2004-06-03 |
Bett Andrew J. |
Methods for propagating adenovirus and virus produced thereby
|
|
US20040166091A1
(en)
*
|
2003-02-24 |
2004-08-26 |
Genvec, Inc. |
Materials and methods for treating disorders of the ear
|
|
ES2391975T3
(es)
*
|
2003-07-25 |
2012-12-03 |
Genvec, Inc. |
Vacunas a base de vector adenovírico
|
|
EP1687032B1
(en)
*
|
2003-11-14 |
2010-02-24 |
Genvec, Inc. |
Pharmaceutical composition for treating unresectable, locally advanced pancreatic cancer (lapc).
|
|
AU2004293474B2
(en)
*
|
2003-11-24 |
2010-12-23 |
Canji, Inc. |
Reduction of dermal scarring
|
|
CA2555412C
(en)
*
|
2004-02-23 |
2013-06-25 |
Crucell Holland B.V. |
Virus purification methods
|
|
WO2005110492A2
(en)
|
2004-04-12 |
2005-11-24 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method of using adenoviral vectors to induce an immune response
|
|
EP1769077A2
(en)
*
|
2004-07-20 |
2007-04-04 |
The University Of Warwick |
Adenovirus vector and method to manipulate the adenovirus genome
|
|
WO2006039045A2
(en)
*
|
2004-09-01 |
2006-04-13 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adenoviral vectors able to transduce apcs, potential use in immune response generation
|
|
WO2006086357A2
(en)
*
|
2005-02-10 |
2006-08-17 |
Merck & Co., Inc. |
Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby
|
|
ATE412737T1
(de)
*
|
2005-04-11 |
2008-11-15 |
Crucell Holland Bv |
Virusreinigung mit ultrafiltration
|
|
US9651543B2
(en)
|
2005-08-31 |
2017-05-16 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
|
EP1929021A2
(en)
*
|
2005-08-31 |
2008-06-11 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
|
US8450055B2
(en)
*
|
2005-08-31 |
2013-05-28 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
|
EP1951297A2
(en)
*
|
2005-11-10 |
2008-08-06 |
GenVec, Inc. |
Adenoviral vector-based foot-and-mouth disease vaccine
|
|
CA2675022A1
(en)
*
|
2007-01-09 |
2008-07-17 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
|
US20090202492A1
(en)
*
|
2008-01-25 |
2009-08-13 |
University Of South Florida |
Adenovirus vaccine utilizing ikk as adjuvant
|
|
CN102056624A
(zh)
*
|
2008-06-04 |
2011-05-11 |
康奈尔大学 |
用于防治成瘾的疫苗
|
|
ES2532015T3
(es)
|
2008-11-03 |
2015-03-23 |
Crucell Holland B.V. |
Método para la producción de vectores adenovíricos
|
|
US9605844B2
(en)
*
|
2009-09-01 |
2017-03-28 |
Cree, Inc. |
Lighting device with heat dissipation elements
|
|
WO2011045378A1
(en)
|
2009-10-15 |
2011-04-21 |
Crucell Holland B.V. |
Method for the purification of adenovirus particles
|
|
MX2012004221A
(es)
|
2009-10-15 |
2012-06-08 |
Crucell Holland Bv |
Proceso para purificacion de adenovirus de cultivos de alta densidad celular.
|
|
US20120219583A1
(en)
|
2009-10-16 |
2012-08-30 |
Los Alamos National Security, Llc |
Nucleic acid sequences encoding expandable hiv mosaic proteins
|
|
US9133248B2
(en)
|
2009-11-09 |
2015-09-15 |
Genvec, Inc. |
Methods of propagating monkey adenoviral vectors
|
|
WO2011057254A2
(en)
|
2009-11-09 |
2011-05-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Simian adenoviral vector-based vaccines
|
|
ES2578514T3
(es)
|
2010-02-15 |
2016-07-27 |
Crucell Holland B.V. |
Método para la producción de vectores adenovíricos
|
|
EP2547362B1
(en)
|
2010-03-17 |
2021-08-25 |
Cornell University |
Disrupted adenovirus-based vaccine against drugs of abuse
|
|
KR20180108886A
(ko)
|
2010-03-23 |
2018-10-04 |
인트렉손 코포레이션 |
치료적 단백질을 조건부로 발현하는 벡터，상기 벡터를 포함하는 숙주 세포 및 이의 용도
|
|
WO2012021730A2
(en)
|
2010-08-11 |
2012-02-16 |
Genvec, Inc. |
Respiratory syncytial virus (rsv) vaccine
|
|
CN103118702A
(zh)
|
2010-09-20 |
2013-05-22 |
克鲁塞尔荷兰公司 |
活动性结核病的治疗性接种
|
|
AU2011310838B2
(en)
|
2010-09-27 |
2015-11-05 |
Crucell Holland B.V. |
Heterologous prime boost vaccination regimen against malaria
|
|
WO2012083297A2
(en)
|
2010-12-17 |
2012-06-21 |
Genvec, Inc. |
Adenoviral vectors with modified hexon regions
|
|
WO2012088041A1
(en)
|
2010-12-20 |
2012-06-28 |
Genvec, Inc. |
Adenoviral vector-based dengue fever vaccine
|
|
US9402919B2
(en)
|
2011-03-04 |
2016-08-02 |
Intrexon Corporation |
Vectors conditionally expressing protein
|
|
WO2012162428A1
(en)
|
2011-05-23 |
2012-11-29 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Prime-boost vaccination for viral infection
|
|
EP2764011B1
(en)
|
2011-10-05 |
2021-04-07 |
GenVec, Inc. |
Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
|
|
CN103974970B
(zh)
|
2011-10-05 |
2018-01-02 |
金维克有限公司 |
猴腺病毒(大猩猩)或腺病毒载体及其使用方法
|
|
CN107574154A
(zh)
|
2011-10-05 |
2018-01-12 |
金维克有限公司 |
猴(大猩猩)腺病毒或腺病毒载体及其使用方法
|
|
BR112014008167B1
(pt)
|
2011-10-05 |
2022-05-24 |
Genvec Inc |
Adenovírus ou vetor adenoviral e composição os compreendendo
|
|
EP2780034A1
(en)
|
2011-11-14 |
2014-09-24 |
Crucell Holland B.V. |
Heterologous prime-boost immunization using measles virus-based vaccines
|
|
WO2013116591A1
(en)
|
2012-02-02 |
2013-08-08 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccine
|
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
|
ES2582504T3
(es)
|
2012-03-12 |
2016-09-13 |
Crucell Holland B.V. |
Lotes de adenovirus recombinantes con extremos alterados
|
|
US9125870B2
(en)
|
2012-03-22 |
2015-09-08 |
Crucell Holland B.V. |
Vaccine against RSV
|
|
MY169331A
(en)
|
2012-03-22 |
2019-03-21 |
Janssen Vaccines & Prevention Bv |
Vaccine against rsv
|
|
US10004811B2
(en)
|
2012-04-13 |
2018-06-26 |
Cornell University |
Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
|
|
US9676824B2
(en)
|
2012-05-29 |
2017-06-13 |
Genvec, Inc. |
Herpes simplex virus vaccine
|
|
WO2013181128A1
(en)
|
2012-05-29 |
2013-12-05 |
Genvec, Inc. |
Modified serotype 28 adenoviral vectors
|
|
EP4421177A3
(en)
|
2013-03-13 |
2024-12-18 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Prefusion rsv f proteins and their use
|
|
TR201902513T4
(tr)
|
2013-04-25 |
2019-03-21 |
Janssen Vaccines & Prevention Bv |
Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri.
|
|
KR102313153B1
(ko)
|
2013-06-17 |
2021-10-15 |
얀센 백신스 앤드 프리벤션 비.브이. |
안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
|
|
PE20160527A1
(es)
|
2013-09-19 |
2016-05-20 |
Crucell Holland Bv |
Formulaciones de adenovirus mejoradas
|
|
WO2016037154A1
(en)
|
2014-09-04 |
2016-03-10 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Recombinant hiv-1 envelope proteins and their use
|
|
EP3189147A1
(en)
|
2014-09-07 |
2017-07-12 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
|
|
TWI710635B
(zh)
|
2014-10-09 |
2020-11-21 |
美商珍維克公司 |
編碼人類無調同源物-1(hath1)之腺病毒載體
|
|
JP6325751B2
(ja)
|
2014-11-04 |
2018-05-16 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． |
治療用ｈｐｖ１６ワクチン
|
|
WO2016103238A1
(en)
|
2014-12-24 |
2016-06-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant metapneumovirus f proteins and their use
|
|
CA2974359A1
(en)
|
2015-01-20 |
2016-07-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant parainfluenza virus expressing a chimeric f protein and uses thereof
|
|
KR20170140180A
(ko)
|
2015-02-24 |
2017-12-20 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도
|
|
SI3271729T1
(sl)
|
2015-03-18 |
2021-04-30 |
Janssen Vaccines & Prevention B.V. |
Testi za rekombinantne ekspresijske sisteme
|
|
US10570417B2
(en)
|
2015-04-14 |
2020-02-25 |
Janssen Vaccines & Prevention B.V. |
Recombinant adenovirus expressing two transgenes with a bidirectional promoter
|
|
US10457708B2
(en)
|
2015-07-07 |
2019-10-29 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion RSV F polypeptides
|
|
WO2017005844A1
(en)
|
2015-07-07 |
2017-01-12 |
Janssen Vaccines & Prevention B.V. |
Vaccine against rsv
|
|
JP6470872B2
(ja)
|
2015-08-20 |
2019-02-13 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． |
治療用ｈｐｖ１８ワクチン
|
|
CA3001050C
(en)
|
2015-10-06 |
2023-03-28 |
Janssen Vaccines & Prevention B.V. |
Method for preventing surface-induced degradation of viruses using cyclodextrins
|
|
WO2017139392A1
(en)
|
2016-02-08 |
2017-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant hiv-1 envelope proteins and their use
|
|
WO2017156272A1
(en)
|
2016-03-09 |
2017-09-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant hiv-1 envelope proteins and their use
|
|
MY190320A
(en)
|
2016-04-05 |
2022-04-13 |
Janssen Vaccines & Prevention Bv |
Stabilized soluble pre-fusion rsv f proteins
|
|
KR102401247B1
(ko)
|
2016-04-05 |
2022-05-25 |
얀센 백신스 앤드 프리벤션 비.브이. |
Rsv에 대한 백신
|
|
SG11201808809PA
(en)
|
2016-05-02 |
2018-11-29 |
Janssen Vaccine & Prevention B V |
Therapeutic hpv vaccine combinations
|
|
EP3455358B1
(en)
|
2016-05-12 |
2020-08-26 |
Janssen Vaccines & Prevention B.V. |
Potent and balanced bidirectional promoter
|
|
CA3025441A1
(en)
|
2016-05-30 |
2017-12-07 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion rsv f proteins
|
|
CN109312362B
(zh)
|
2016-06-20 |
2022-06-28 |
扬森疫苗与预防公司 |
有效和平衡的双向启动子
|
|
JP7229151B2
(ja)
|
2016-07-14 |
2023-02-27 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
Ｈｐｖワクチン
|
|
CA3038968A1
(en)
|
2016-09-30 |
2018-04-05 |
Genvec, Inc. |
Adenovectors for delivery of therapeutic genetic material into t cells
|
|
WO2018067582A2
(en)
|
2016-10-03 |
2018-04-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Hiv-1 env fusion peptide immunogens and their use
|
|
WO2018081318A1
(en)
|
2016-10-25 |
2018-05-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Prefusion coronavirus spike proteins and their use
|
|
WO2018109220A2
(en)
|
2016-12-16 |
2018-06-21 |
Institute For Research In Biomedicine |
Novel recombinant prefusion rsv f proteins and uses thereof
|
|
WO2018129268A1
(en)
|
2017-01-07 |
2018-07-12 |
Selecta Biosciences, Inc. |
Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
|
|
CN110268061B
(zh)
|
2017-02-09 |
2024-07-16 |
扬森疫苗与预防公司 |
用于表达异源基因的有效的短启动子
|
|
US11235056B2
(en)
|
2017-03-24 |
2022-02-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Glycan-masked engineered outer domains of HIV-1 gp120 and their use
|
|
PL3601367T3
(pl)
|
2017-03-30 |
2025-03-31 |
The University Of Queensland |
Cząsteczki chimeryczne i ich zastosowania
|
|
JP2020519663A
(ja)
|
2017-05-17 |
2020-07-02 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． |
Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
|
|
EP4400174A3
(en)
|
2017-09-01 |
2024-10-23 |
The Francis Crick Institute Limited |
Immunoregulatory molecules and uses therefor
|
|
KR20200053518A
(ko)
|
2017-09-15 |
2020-05-18 |
얀센 백신스 앤드 프리벤션 비.브이. |
Rsv에 대한 면역의 안전한 유도를 위한 방법
|
|
US20190142974A1
(en)
|
2017-10-13 |
2019-05-16 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector igm responses
|
|
WO2019079337A1
(en)
|
2017-10-16 |
2019-04-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE
|
|
KR20200083510A
(ko)
|
2017-10-31 |
2020-07-08 |
얀센 백신스 앤드 프리벤션 비.브이. |
아데노바이러스 및 이의 용도
|
|
MX421606B
(es)
|
2017-10-31 |
2025-03-14 |
Janssen Vaccines & Prevention Bv |
Vectores adenovirales y usos de estos
|
|
EP3704138A1
(en)
|
2017-10-31 |
2020-09-09 |
Janssen Vaccines & Prevention B.V. |
Adenovirus and uses thereof
|
|
EA202091074A1
(ru)
|
2017-10-31 |
2020-07-22 |
Янссен Вэксинс Энд Превеншн Б.В. |
Аденовирус и его применения
|
|
JP7317047B2
(ja)
|
2018-01-23 |
2023-07-28 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
インフルエンザウイルスワクチン及びその使用
|
|
EP3758682A4
(en)
|
2018-02-26 |
2021-12-15 |
Antolrx, Inc. |
TOLEROGENIC LIPOSOMES AND THEIR PROCEDURES FOR USE
|
|
IL277128B2
(en)
|
2018-03-06 |
2025-11-01 |
Precigen Inc |
Hepatitis b vaccines and uses of the same
|
|
WO2019173465A1
(en)
|
2018-03-06 |
2019-09-12 |
Intrexon Corporation |
Human papillomavirus vaccines and uses of the same
|
|
US12162910B2
(en)
|
2018-10-22 |
2024-12-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant gp120 protein with V1-loop deletion
|
|
JOP20210106A1
(ar)
|
2018-11-13 |
2023-01-30 |
Janssen Vaccines And Prevention B V |
بروتينات rsv f سابقة الاندماج مستقرة
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
MX2021012991A
(es)
|
2019-04-25 |
2021-12-10 |
Janssen Vaccines & Prevention Bv |
Antigenos de gripe recombinantes.
|
|
CA3138525A1
(en)
|
2019-04-28 |
2020-11-05 |
Selecta Biosciences, Inc. |
Methods for treatment of subjects with preexisting immunity to viral transfer vectors
|
|
JP2022532723A
(ja)
|
2019-05-15 |
2022-07-19 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
季節性インフルエンザワクチン及びアデノウイルス系呼吸器合胞体ウイルスワクチンの共投与
|
|
MX2021013947A
(es)
|
2019-05-15 |
2021-12-14 |
Janssen Vaccines & Prevention Bv |
Tratamiento profilactico de la infeccion por virus sincitial respiratorio con una vacuna basada en adenovirus.
|
|
MX2021014566A
(es)
|
2019-05-28 |
2022-03-22 |
Selecta Biosciences Inc |
Métodos y composiciones para la respuesta inmune atenuada anti-vector de transferencia viral.
|
|
KR20220057578A
(ko)
|
2019-09-05 |
2022-05-09 |
얀센 백신스 앤드 프리벤션 비.브이. |
인플루엔자 바이러스 백신 및 이의 용도
|
|
BR112022005268A2
(pt)
|
2019-10-03 |
2022-08-16 |
Janssen Vaccines & Prevention Bv |
Vetores adenovirais e usos dos mesmos
|
|
EP4041873A4
(en)
|
2019-10-08 |
2023-10-25 |
Trustees of Boston College |
PROTEINS CONTAINING SEVERAL DIFFERENT UNNATURAL AMINO ACIDS AND METHODS FOR PRODUCING AND USING SUCH PROTEINS
|
|
CA3161800A1
(en)
|
2019-11-18 |
2021-05-27 |
Janssen Biotech, Inc. |
Vaccines based on mutant calr and jak2 and their uses
|
|
JP7769388B2
(ja)
|
2019-12-12 |
2025-11-13 |
ティン セラピューティクス，インコーポレイテッド |
聴覚損失の予防及び治療のための組成物及び方法
|
|
BR112022015628A2
(pt)
|
2020-02-11 |
2022-09-27 |
Us Health |
Vacina de sars-cov-2
|
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
|
CN115484978A
(zh)
|
2020-03-05 |
2022-12-16 |
尼奥克斯医疗有限公司 |
使用免疫细胞治疗癌症的方法和组合物
|
|
US11213482B1
(en)
|
2020-03-05 |
2022-01-04 |
University of Pittsburgh—Of the Commonwealth System of Higher Educat |
SARS-CoV-2 subunit vaccine and microneedle array delivery system
|
|
US11773391B2
(en)
|
2020-04-01 |
2023-10-03 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
|
|
JP2023521194A
(ja)
|
2020-04-13 |
2023-05-23 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｐｓｍａ及びｓｔｅａｐ１ワクチン並びにそれらの使用
|
|
EP4142785A2
(en)
|
2020-04-29 |
2023-03-08 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Recombinant human metapneumovirus f proteins and their use
|
|
WO2022009051A1
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
A method for determining responsiveness to prostate cancer treatment
|
|
US12295997B2
(en)
|
2020-07-06 |
2025-05-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
WO2022009049A1
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
WO2022035860A2
(en)
|
2020-08-10 |
2022-02-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Replication-competent adenovirus type 4-hiv env vaccines and their use
|
|
US20240228549A1
(en)
|
2021-04-29 |
2024-07-11 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Prefusion-stabilized lassa virus glycoprotein complex and its use
|
|
WO2023015186A1
(en)
|
2021-08-03 |
2023-02-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
|
|
US20230141563A1
(en)
|
2021-10-12 |
2023-05-11 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector igm responses
|
|
WO2023091696A1
(en)
|
2021-11-19 |
2023-05-25 |
Christiana Care Gene Editing Institute, Inc. |
Adenovirus delivery system for cancer treatment
|
|
WO2023172624A1
(en)
|
2022-03-09 |
2023-09-14 |
Selecta Biosciences, Inc. |
Immunosuppressants in combination with anti-igm agents and related dosing
|
|
WO2023192835A1
(en)
|
2022-03-27 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Base-covered hiv-1 envelope ectodomains and their use
|
|
WO2023196898A1
(en)
|
2022-04-07 |
2023-10-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Beta globin mimetic peptides and their use
|
|
EP4338727A1
(en)
|
2022-09-14 |
2024-03-20 |
Roquette Freres |
Adenovirus formulations
|
|
WO2024233783A1
(en)
|
2023-05-09 |
2024-11-14 |
Cornell University |
Expression cassette coding for vascular endothelial growth factor
|
|
WO2024249626A1
(en)
|
2023-05-30 |
2024-12-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Hiv-1 envelope triple tandem trimers and their use
|
|
WO2025158316A1
(en)
|
2024-01-26 |
2025-07-31 |
Janssen Biotech, Inc. |
Ovarian neoantigens and use thereof
|